Kurimchak A.; Shelton C.; Duncan K.; Johnson K.; Brown J.; O'Brien S.; Gabbasov R.; Fink L.; Li Y.; Lounsbury N.; Abou-Gharbia M.; Childers W.; Connolly D.; Chernoff J.; Peterson J.; Duncan J.
(2016)
© 2016 The Author(s)Small-molecule BET bromodomain inhibitors (BETis) are actively being pursued in clinical trials for the treatment of a variety of cancers, but the mechanisms of resistance to BETis remain poorly understood. ...